Bristol Myers Squibb Reports observational study Data for Enfortumab vedotin in Renal cell carcinoma

Bristol Myers Squibb today announced observational study results for Enfortumab vedotin in patients with Renal cell carcinoma. The study demonstrated that Enfortumab vedotin improves quality of life measures compared to standard of care or placebo. These results provide important insights into the treatment of Renal cell carcinoma and support the continued development of Enfortumab vedotin in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results. The safety profile of Enfortumab vedotin was consistent with previous observations, with no new safety signals identified.